Company news

Wuxi Biologics (Cayman) Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

WuXi Biologics Continues to Be Included in Multiple Hang Seng Sustainability Indexes, Demonstrating ESG Excellence

October 14, 2026

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026

October 7, 2026

Interim Report 2026

September 22, 2026

Next Day Disclosure Return

September 18, 2026

WuXi Biologics Reports Strong Profitable Growth in H1 2026

August 25, 2026

WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO

August 18, 2026

WuXi Biologics Cayman Announces Divestment of Controlling Stake in Bestchrom

August 13, 2026

WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO

July 28, 2026

WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy

July 9, 2026

WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year

July 8, 2026

WuXi Biologics Cayman Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year

July 7, 2026

WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapy

June 30, 2026

WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations

June 24, 2026

WuXi Biologics Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market

June 19, 2026

WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market

June 18, 2026

Wuxi Biologics (Cayman): Included in S&P Global Sustainability Yearbook (China Edition) for Fourth Consecutive Year

June 11, 2026

WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards

June 8, 2026

WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility

June 4, 2026

WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year

June 2, 2026

WuXi Biologics Cayman Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year

June 1, 2026

WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities

May 27, 2026

WuXi Biologics Hosts Third CRDMO Day in Japan, Accelerating Biopharma Innovation from IND to Commercialization

May 20, 2026

WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index

May 12, 2026

WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access

April 29, 2026

WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival

April 24, 2026

WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics

April 23, 2026

WuXi Biologics Recognized by Morningstar Sustainalytics as Industry and Regional ESG Leader for Sixth Year

April 17, 2026

WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing

April 14, 2026

WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year

March 30, 2026

WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture

March 25, 2026

WuXi Biologics Reports Record 2025 Annual Results

March 24, 2026

World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target

March 21, 2026

WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation

March 12, 2026

Earendil Labs and WuXi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Bispecific/Multispecific Antibodies and ADCs

March 12, 2026

WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year

March 1, 2026

WuXi Vaccines Receives Brazil's ANVISA GMP Certification

February 11, 2026

WuXi Biologics Awarded EcoVadis Platinum Medal for Third Consecutive Year, Ranking Among Top 1% Globally

February 8, 2026

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

February 2, 2026

WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

January 28, 2026

WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline

January 26, 2026

HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline

January 26, 2026

JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

January 14, 2026

WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic

January 12, 2026

WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing

January 12, 2026

WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement

January 4, 2026

WuXi Biologics Recognized by Hong Kong ESG Reporting Awards 2025 for Outstanding ESG Disclosure

December 23, 2025

WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security

December 19, 2025

WuXi Biologics Extends Global CRDMO Network to Qatar Through Strategic MoU Signed with Qatar Free Zones Authority

December 2, 2025

WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index

October 21, 2025

WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition by Frost & Sullivan

October 20, 2025

Older news releases →

Decks

The 5 newest of 24 decks. Every deck is listed under its year.